A new oral medicine for anemia in dialysis patients
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are on dialysis (hemodialysis or peritoneal dialysis) for at least 16 weeks.
- You have been receiving a medicine for anemia (like epoetin) for at least 6 weeks.
- Your hemoglobin level is between 9.0 and 12.0 g/dL.
- Your iron levels are adequate (your doctor will check).
- You do not have serious health issues like uncontrolled high blood pressure, recent heart attack or stroke, active liver disease, or seizures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.
This trial tests an experimental drug called AND017 for people with a certain type of myelodysplastic syndrome (MDS) that is low-risk and not linked to a chromosome 5 deletion. The goal is to see if AND017 can help improve low red blood cell counts (anemia) and reduce or avoid the need for blood transfusions.
This trial tests a new oral medication (QLG1218, also called daprodustat) to treat anemia in people with chronic kidney disease who are on hemodialysis. It is comparing the new drug to the usual injected ESA medicines to see if it works as well or better.
This trial tests an experimental drug called AND017 to treat anemia (low red blood cells) in people with cancer who are not currently receiving chemotherapy. The goal is to see if it can raise hemoglobin levels and improve energy.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
Hear when a new Anemia Due to Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.